Meeting
2021 ASCO Annual Meeting
Clinicogenomic real-world data analysis of patients (pts) with KRAS G12C-mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST).
Authors
Rafal Dziadziuszko
Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
Rafal Dziadziuszko , Xiao Li , Eric C. Anderson , Alona Zer , Luis Corrales-Rodriguez , Parneet Cheema , Aleksandra Szczesna , Manuel Philco , Michael Mathisen , Sarah M. Paul , Vijay Bhagawati-Prasad , Gaurav Pathria , Zhen Shi , Magalie Hilton , qing zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03178552
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9023)
DOI
10.1200/JCO.2021.39.15_suppl.9023
Abstract #
9023
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer.
First Author: Kathryn C. Arbour
Poster
2023 ASCO Annual Meeting
Molecular characterization of resistance to immune checkpoint inhibitor and chemotherapy treatment in advanced non-small cell lung cancer.
First Author: Jordan Kardos
Poster
2023 ASCO Annual Meeting
The genomic, transcriptomic, and immunological landscape of SGLT2 in lung cancer.
First Author: Heng Tan
Poster
2022 ASCO Annual Meeting
Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial.
First Author: Alessio Cortellini